Swiss dermal filler expert Teoxane has inked an exclusive distribution deal with US-based biotech company Revance Therapeutics.
The agreement gives Revance the rights to commercialise Teoxane’s RHA line of fillers in the US; starting with its FDA-approved RHA 2, RHA 3 and RHA 4 products, as well as Teoxane’s RHA 1 dermal filler, which is currently undergoing clinical trials.
In exchange for access to Teoxane’s RHA product line, the company was issued with 2.5 million of Revance’s shares.
Mark Foley Revance’s CEO and President said the deal would be “transformational” for the company.
“This is a transformational deal for Revance, giving us access to the fast-growing, billion-dollar US dermal filler market, with a line of highly differentiated fillers that are complementary to our first and only, long-lasting neuromodulator.
“This deal provides commercial synergies, organisational leverage and fast-tracks the buildout of our sales organisation.
“It also creates a broad function from which to launch Daxi upon anticipated approval last year.”
Revance’s Daxi product combines a proprietary stabilising peptide excipient with a purified botulinum toxin, and is expected to launch in spring 2020 upon regulatory approval.
“We are eager to introduce US physicians and consumers to our exciting, highly differentiated RHA range of dermal fillers,” added Teoxane’s CEO and founder Valérie Taupin.
“The combination of our RHA filler range with Revance’s cutting-edge neuromodulator, Daxi, will create a premium facial injectable portfolio that we believe will be unrivalled in the industry.”
